Sakado, Japan
Sakado, Japan

Jōsai University is a private university in Sakado, Saitama, Japan, established in 1965. The predecessor of the school, Jōsai Gakuen Middle School, later Jōsai High School, was founded in 1918. The university is operated by the Jōsai University Educational Corporation, which was founded by the 17th Minister of Finance, Mikio Mizuta . Mizuta was Minister of Finance from 1960 to 1962, and then served as the first chancellor of Jōsai. The university opened with a Faculty of Economics and Faculty of Science. The Mizuta Museum of Art opened in 1976, and the graduate school of Jōsai University was established in 1977. The Jōsai University Educational Corporation also operates Josai International University, founded in 1992. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Josai University | Date: 2016-10-13

The present invention relates to a therapeutic agent for inflammation in which histone is involved, the agent comprising a monoclonal antibody or an antigen binding fragment thereof which binds to a peptide consisting of an amino acid sequence represented by SSVLYGGPPSAA (SEQ ID NO:1) or a conjugate of the peptide and a pharmaceutically acceptable carrier.


Patent
Kowa Company and Josai University | Date: 2012-05-04

A medicament for promoting proliferation of hepatocytes and liver regeneration, which comprises a polyprenyl compound such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient.


Patent
Josai University and Kowa Company. Ltd. | Date: 2010-03-31

A medicament for promoting proliferation of hepatocytes and liver regeneration, which comprises a polyprenyl compound such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient.


Indole alkaloid derivatives having an opioid receptor agonistic effect, their synthesis, and therapeutic compositions containing these derivatives, and methods of treating conditions with these compounds and therapeutic compositions, are provided.


Nakajima K.,Josai University
Current Clinical Pharmacology | Year: 2010

People with metabolic syndrome (MetS) are at increased risk of type 2 diabetes and cardiovascular diseases, and often have increased triglyceride, reduced high-density lipoprotein cholesterol (HDL-C) and sometimes moderately increased low-density lipoprotein cholesterol (LDL-C) levels. Lifestyle intervention is critical for treating MetS, while pharmacotherapy of dyslipidemia in MetS remains controversial. Considering the specific lipid profile in MetS, fibrates are typically used as first-line treatment. Nevertheless, first-line therapy should be directed towards LDL-C, even in people with MetS, because of the evidence that lowering LDL-C has cardioprotective effects. Non-HDL-C is considered to be an alternative treatment target for people with moderately or severely elevated triglyceride (≥200mg/dl). Statins improve lipid profiles principally by lowering LDL-C and may exert anti-inflammatory and anti-atherothrombogenic effects, which ameliorate the fundamental pathophysiology of MetS. Fibrates also have pleiotropic effects that improve cardiometabolic risk factors, including insulin resistance, although they do not have clear cardioprotective effects. Omega-3 fatty acids, niacin, pioglitazone and anti-obesity drugs are also candidates for the treatment of dyslipidemia and other complications in MetS. Another question is whether statins in combination with fibrates or other lipid-lowering drugs has greater cardioprotective properties than monotherapy. In this article, we discuss several issues in the pharmacotherapy of MetS. © 2010 Bentham Science Publishers Ltd.


Patent
Josai University | Date: 2013-02-22

The present invention relates to a therapeutic agent for inflammation in which histone is involved, the agent comprising a monoclonal antibody or an antigen binding fragment thereof which binds to a peptide consisting of an amino acid sequence represented by SSVLYGGPPSAA (SEQ ID NO:1) or a conjugate of the peptide and a pharmaceutically acceptable carrier.


The present invention relates to a monoclonal antibody having excellent immunosuppressive activity or an antigen binding fragment thereof. More specifically, the present invention relates to a monoclonal antibody or an antigen binding fragment thereof, which binds to a peptide consisting an amino acid sequence represented by SSVLYGGPPSAA (SEQ ID NO: 1) or a conjugate of the peptide and a pharmaceutically acceptable carrier, the monoclonal antibody or an antigen binding fragment thereof having a higher binding affinity for core histone than for histone H1.


It is an object of the present invention to provide a method and an apparatus capable of noninvasively administrating vaccine through the skin, and thereby making the immune response activate. A drug product according to the present invention is characterized in that the drug product has a support medium, an electrode formed on the support medium and protected partly by an insulating material for avoiding a direct cutaneous contact, a vaccine containing layer for containing a vaccine, wherein the vaccine is an antigen for inducing an immune suppression protein. A method of administrating a vaccine according to the present invention is characterized in that the vaccine is administrated by the iontophoresis using the drug product according to the drug product of the present invention as an electrode. An apparatus for the iontophoresis according to the present invention is characterized in that the drug product according to the present invention is used as an electrode.


Patent
Josai University | Date: 2014-12-24

The present invention relates to a therapeutic agent for inflammation in which histone is involved, the agent comprising a monoclonal antibody or an antigen binding fragment thereof which binds to a peptide consisting of an amino acid sequence represented by SSVLYGGPPSAA (SEQ ID NO:1) or a conjugate of the peptide and a pharmaceutically acceptable carrier.


The present invention relates to a monoclonal antibody having excellent immunosuppressive activity or an antigen binding fragment thereof. More specifically, the present invention relates to a monoclonal antibody or an antigen binding fragment thereof, which binds to a peptide consisting an amino acid sequence represented by SSVLYGGPPSAA (SEQ ID NO: 1) or a conjugate of the peptide and a pharmaceutically acceptable carrier, the monoclonal antibody or an antigen binding fragment thereof having a higher binding affinity for core histone than for histone H1.

Loading Josai University collaborators
Loading Josai University collaborators